May 30, 2019
Trovagene to Host Business Update Conference Call on June 7, 2019
May 23, 2019
Trovagene Announces Research Collaboration with Nektar Therapeutics to Evaluate Efficacy of the Combination of Onvansertib and ONZEALD(TM) in Models of Colorectal Cancer
May 13, 2019
Trovagene Announces Equity Investment of $1.5 Million at Premium to Market Price from Institutional Investor, Lincoln Park Capital
Apr 23, 2019
Trovagene Announces Data Demonstrating Significant Synergy of Onvansertib in Combination with Venetoclax in Cell Model of Venetoclax-Resistant AML
Apr 05, 2019
Trovagene Announces Update to Phase 1b/2 AML Trial Data Presented at AACR - Additional Patients Achieve Complete Response at Two Highest Dose Levels of Onvansertib
Apr 05, 2019
Trovagene Announces $1.5 Million Equity Investment at Premium to Market from Institutional Investor, Lincoln Park Capital
Apr 02, 2019
Early Data from Phase 2 Trial Indicates Activity of Onvansertib in Prostate Cancer Patients Showing Initial Resistance to Anti-Androgen Therapy
Mar 13, 2019
Trovagene Receives Approximately $3.0 Million From Exercise of Warrants
Feb 19, 2019
Trovagene, Inc. Announces Reverse Stock Split
Feb 14, 2019
Trovagene Presents Update on Phase 2 Study of Onvansertib in Combination with Zytiga in Patients with mCRPC at ASCO-GU Conference
Jan 23, 2019
Trovagene Announces New Patent Issued for Combination of Onvansertib with Anti-Androgen Drugs to Treat Non-Metastatic and Metastatic Prostate Cancer
Dec 03, 2018
New Data from Phase 1b/2 Study of Onvansertib in Combination with LDAC or Decitabine Demonstrates Response to Treatment in Relapsed/Refractory AML
Nov 15, 2018
Trovagene, Inc. Receives Positive Nasdaq Listing Decision
Nov 13, 2018
Trovagene Announces Launch of New Company Website
Nov 07, 2018
Trovagene Announces Third Quarter 2018 Highlights and Financial Results
Nov 01, 2018
Trovagene to Present Data from Lead Clinical Program of Onvansertib in Acute Myeloid Leukemia at the 60th American Society of Hematology Annual Meeting
Oct 24, 2018
Trovagene Announces New Patent Claim Allowances Affirming Broad Patent Portfolio Coverage of NPM1 Mutations by U.S. Patent and Trademark Office
Oct 18, 2018
Trovagene to Provide Update on Onvansertib Clinical Development Program on Wednesday, October 24, 2018
Oct 03, 2018
Trovagene Announces Exclusive License Agreement with MIT for Combination Therapy of Anti-Androgens and Polo-like Kinase Inhibitors in Prostate Cancer
Sep 27, 2018
Trovagene Announces Completion of Dosing Cohort of Patients Treated with Onvansertib in Combination with Decitabine in Ongoing Phase 1b/2 AML Trial